查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929648

口腔崩解片市場按產品類型、技術、治療領域、通路和最終用戶分類，全球預測（2026-2032年）

Oral Disintegrating Strips Market by Product Type, Technology, Therapeutic Area, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，口腔崩壞片市場價值將達到 24.7 億美元，到 2026 年將成長至 26.6 億美元，到 2032 年將達到 39.2 億美元，年複合成長率為 6.79%。

關鍵市場統計數據
基準年 2025 24.7億美元
預計年份：2026年 26.6億美元
預測年份 2032 39.2億美元
複合年成長率 (%) 6.79%

口腔崩壞片簡介：重點關注配方優勢、以患者為中心的益處、不斷發展的生產技術以及醫療保健領域的監管動態

口腔崩壞片是一種創新的給藥形式，兼具便利性、病患依從性和製劑柔軟性。這種薄膜與唾液接觸後迅速溶解，無需用水即可給藥，有助於提高吞嚥困難患者的用藥依從性。這項技術在眾多治療領域中日益重要，尤其是在快速起效、劑量精準和患者體驗至關重要的領域，例如隨時隨地緩解症狀、兒童用藥以及吞嚥障礙常見的老年護理。

製劑技術、病患行為、生產規模化和監管政策的變革性變化正在重塑口腔崩壞片的推廣應用路徑。

口腔崩壞片的最新發展趨勢是技術進步和終端用戶需求不斷變化共同作用的結果。製劑科學已超越了基本的薄膜基質，涵蓋了掩味策略、緩釋技術以及使用共加工輔料來增強其在潮濕環境中的穩定性。這些技術進步降低了性能差異，並拓寬了治療範圍，促使那些先前認為此類劑型僅限於特定適應症的研發人員開始採用。

評估2025年美國關稅對口溶錠供應鏈韌性、原料成本、配方調整方案和策略採購規劃的影響

美國將於2025年生效的新關稅將為依賴跨境供應鏈獲取原料、輔料和契約製造服務的相關人員帶來新的營運挑戰。關稅調整將改變單位成本，並可能對利潤率較低的產品線或依賴進口特種聚合物或活性藥物成分的產品線產生特別顯著的影響。從高關稅地區採購成膜輔料或專有輔料的公司可能面臨更高的投入成本，這將迫使它們重新評估供應商合約和庫存策略。

我們透過細分分析來指導產品策略，整合了銷售形式、最終用戶人口統計、分銷管道、配方技術和治療領域差異化。

細分市場分析揭示了不同銷售形式、最終用戶、分銷管道、技術和治療領域所帶來的獨特機會和發展考量。基於銷售形式，配方和包裝設計必須滿足非處方藥 (OTC) 和處方藥 (處方箋) 的監管要求和消費者期望。這些類別在標籤、給藥說明和患者諮詢方面需要不同的考慮。基於最終用戶，目標族群的特徵會影響口味掩蔽、劑量柔軟性和易用性。成人、老年人和兒童群體各自具有獨特的依從性促進因素和臨床優先事項，這些因素體現在劑量強度和包裝規格上。

為在全球範圍內成功推廣口腔崩壞片，需要考慮區域策略因素以及監管、生產和商業方面的調整。

區域趨勢影響著美洲、歐洲、中東和非洲以及亞太地區的監管、供應鏈設計和商業性執行重點。在美洲，完善的法規結構和成熟的醫藥基礎設施促進了臨床開發和經銷夥伴的精簡，同時以患者為中心的定位和直接面對消費者的銷售管道也日益受到重視。在歐洲、中東和非洲，不同的監管環境和報銷機制意味著市場進入策略必須更加細緻，通常需要根據各國的具體要求制定區域性穩定性策略和標籤策略。

在口腔崩壞片領域，塑造競爭地位的關鍵公司層面差異化因素包括配方平台、生產夥伴關係、品質系統和智慧財產權。

口腔崩壞片市場的競爭格局由那些在配方科學、生產能力和市場關係方面擁有優勢的公司所主導。主要企業透過專有的輔料系統、掩味技術或平台化生產技術脫穎而出，從而實現高載藥量、更高的穩定性和一致的溶出性能。合約研發生產機構 (CDMO) 在為尋求規模化生產或外包生產的客戶提供技術轉移支援和法規文件方面的專業知識方面發揮著至關重要的作用。

為製造商和開發商提供具體策略建議，以確保供應鏈的韌性、最佳化的配方、符合監管要求以及以患者為中心的商業化。

產業領導者應採取務實、以病人為中心的策略，在確保品質和供應連續性的同時，加速產品推廣應用。首先，應使配方開發與明確的終端用戶畫像和通路保持一致，確保針對目標患者和管道最佳化口味掩蔽、片劑大小和包裝。同時，應投資多家檢驗的關鍵輔料供應商，並考慮合格附近或區域合作夥伴，以降低關稅波動和國際物流中斷帶來的風險。

嚴謹的調查方法為策略洞察提供支援：結合關鍵相關人員訪談、技術文獻檢驗、供應商審核和情境分析。

我們的研究途徑結合了與關鍵相關人員的對話、技術文獻綜合和定性檢驗，旨在全面了解口腔崩壞片的市場趨勢。我們與製劑科學家、法規事務負責人、採購人員和銷售主管進行了深入訪談，以收集關於研發挑戰、供應鏈限制因素和市場推廣促進因素的跨職能觀點。這些訪談讓我們得以了解技術權衡、生產準備以及影響通路選擇和標籤標註的實際因素。

對決定口腔崩壞片商業成功的技術進步、終端用戶因素和操作要求進行全面分析

口腔崩壞片正處於一個轉折點，技術成熟度、患者期望和商業性機會在此交匯，為產品差異化開闢了新的途徑。製劑和生產技術的進步正在突破傳統限制，使其能夠更廣泛地應用於不同的治療領域和患者群體。同時，不斷發展的分銷模式和不斷變化的人口結構趨勢也提升了患者友好型、無需用水的劑型的價值，這些劑型有助於提高患者的用藥依從性和滿意度。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按產品類型分類的口腔崩解片市場

  • 處方藥
    • 品牌名稱
    • 學名藥
  • 非處方藥
    • 品牌產品
    • 自有品牌
  • 營養保健品
    • 營養補充品
    • 草本產品

9. 按技術分類的口腔崩解片市場

  • 靜電紡絲
  • 熱熔擠出
  • 溶劑澆鑄

第10章 按治療領域分類的口腔崩解片市場

  • 過敏和感冒
    • 抗組織胺藥物
    • 減充血劑
  • 循環系統
  • 中樞神經系統疾病
  • 消化器官系統
  • 疼痛管理
    • 止痛藥
    • 非類固醇消炎劑（NSAIDs）
  • 維生素和營養補充劑
    • 綜合維他命
    • 單一維生素

第11章 按通路分類的口腔崩解片市場

  • 診所和其他
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 依最終使用者分類的口腔崩解片市場

  • 成人版
  • 老年人
  • 兒童

第13章 口腔崩解片市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 口腔崩解片市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國口腔崩解片市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國口腔崩解片市場

第17章 中國口腔崩解片市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Aquestive Therapeutics, Inc.
  • BioDelivery Sciences International, Inc.
  • Corium International, Inc.
  • CURE Pharmaceutical Holding Corp.
  • GlaxoSmithKline plc
  • Indivior PLC
  • IntelGenx Technologies Corp.
  • Johnson & Johnson
  • LTS Lohmann Therapie-Systeme AG
  • Medherant Limited
  • Merck & Co., Inc.
  • MonoSol Rx LLC
  • NAL Pharma Co., Ltd.
  • Novartis International AG

第18章 20. 其他值得關注的公司：

  • 輝瑞公司
  • 賽諾菲株式會社
  • 住友大日本製藥株式會社
  • 太陽製藥工業有限公司
  • Tesa LabTech
  • Viatris Inc.
  • ZIM Laboratories Limited
Product Code: MRR-0A380695186B

The Oral Disintegrating Strips Market was valued at USD 2.47 billion in 2025 and is projected to grow to USD 2.66 billion in 2026, with a CAGR of 6.79%, reaching USD 3.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.47 billion
Estimated Year [2026] USD 2.66 billion
Forecast Year [2032] USD 3.92 billion
CAGR (%) 6.79%

An introduction to oral disintegrating strips highlighting formulation benefits, patient-centric advantages, manufacturing evolution, and regulatory focus across healthcare settings

Oral disintegrating strips represent an innovative drug delivery format that blends convenience, patient adherence, and formulation flexibility. These thin films dissolve rapidly upon contact with saliva, enabling administrations without water and enhancing compliance among patient groups who experience swallowing difficulties. The technology is increasingly relevant across diverse therapeutic areas where rapid onset, dose accuracy, and patient experience matter, such as on-the-go symptomatic relief, pediatric dosing, or geriatric care settings where dysphagia is common.

Development pathways for these systems intersect formulation science, excipient selection, and manufacturing scalability. Advances in polymer chemistry and film-forming excipients have broadened the range of actives that can be stabilized and delivered effectively in strip form. Simultaneously, manufacturing innovations have reduced production variability and improved content uniformity, addressing earlier commercial hurdles. Regulatory expectations continue to evolve in parallel, placing emphasis on dissolution characteristics, stability under varied humidity conditions, and robust quality control practices to ensure consistent performance across batches.

Taken together, the format is positioned as a patient-centric alternative to traditional oral solid dosage forms, offering manufacturers and healthcare providers new avenues to differentiate products through improved adherence and user experience. As clinical stakeholders increasingly prioritize patient convenience and real-world usability, oral disintegrating strips are moving from niche application toward broader inclusion in product portfolios across therapeutic categories.

Transformative shifts in formulation, patient behavior, manufacturing scale-up, and regulatory clarity that are reshaping adoption pathways for oral disintegrating strips

Recent shifts in the oral disintegrating strips landscape reflect a convergence of technological refinement and evolving end-user expectations. Formulation science has advanced beyond basic film matrices to incorporate taste-masking strategies, controlled-release approaches, and co-processed excipients that enhance stability in humid environments. These technical improvements have reduced performance variability and enabled broader therapeutic application, supporting adoption by developers who previously regarded the format as limited to niche indications.

At the same time, changing healthcare delivery models and patient behaviors are reshaping demand patterns. Expansion of telehealth and direct-to-patient dispensing has elevated the importance of compact, easy-to-administer dosage forms. In parallel, demographic trends such as aging populations and increased prevalence of chronic conditions have intensified interest in formulations that address swallowing difficulties and polypharmacy challenges. Regulatory clarity around quality attributes and bioequivalence expectations has also matured, prompting more robust development programs and enabling clearer commercial pathways.

These shifts are transformative because they intersect across R&D, manufacturing, and commercialization. Developers are now able to leverage platform technologies for faster formulation iterations, manufacturers can scale production with improved process controls, and commercial teams have credible value propositions anchored in adherence and differentiated patient experience. The result is a landscape where oral disintegrating strips are increasingly considered a strategic option rather than a technical curiosity.

Assessment of 2025 United States tariff impacts on supply chain resilience, input costs, reformulation choices, and strategic procurement planning for oral disintegrating strips

The imposition of new tariffs within the United States in 2025 introduces an additional operational dimension for stakeholders that rely on cross-border supply chains for raw materials, excipients, or contract manufacturing services. Tariff adjustments alter unit economics and can disproportionately affect product lines with thin margins or those dependent on specialized imported polymers and active pharmaceutical ingredients. Companies that source film-forming excipients or proprietary additives from regions subject to higher duties may face increased input costs, necessitating reassessment of supplier contracts and inventory strategies.

In response, many firms are accelerating supplier diversification, qualifying alternative domestic or nearshore sources, and negotiating longer-term procurement agreements to stabilize pricing. Some developers and manufacturers are evaluating reformulation pathways that allow substitution of affected components without compromising efficacy or stability, while others are investing in backward integration to secure critical inputs. These strategic responses require close coordination among procurement, regulatory, and quality assurance teams to ensure changes meet performance and compliance requirements.

Additionally, tariff-driven cost pressures may influence commercialization sequencing and pricing strategies. Companies must weigh the trade-offs between maintaining list prices and absorbing incremental costs to protect market access. Ultimately, the tariff environment underscores the importance of resilient supply chains, proactive cost modeling, and flexible formulation strategies to mitigate disruption and sustain product continuity.

Integrated segmentation insights connecting sales type, end-user demographics, distribution channels, formulation technologies, and therapeutic area differentiation to guide product strategy

Segmentation analysis reveals differentiated opportunities and development considerations across sales types, end users, distribution channels, technologies, and therapeutic areas. Based on Sales Type, the formulation and packaging design must respond to the distinct regulatory requirements and consumer expectations associated with Over The Counter and Prescription categories, where labeling, dosing instructions, and patient counseling considerations differ. Based on End User, target population characteristics influence taste-masking, dose flexibility, and ease of handling, with Adult, Geriatric, and Pediatric cohorts each presenting unique adherence drivers and clinical priorities that inform dosage strength and strip size.

Based on Distribution Channel, route-to-patient logistics and presentation requirements vary across Clinics & Others, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, affecting packaging formats, unitization, and returns handling policies. Based on Technology, the choice among Electrospinning, Hot Melt Extrusion, and Solvent Casting determines the achievable drug load, film thickness, and production throughput, with each technique offering trade-offs between scalability and formulation complexity. Based on Therapeutic Area, product design must align with the clinical profile and administration context for categories such as Allergy & Cold, Cardiovascular, CNS Disorders, Gastrointestinal, Pain Management, and Vitamins & Nutritional Supplements, where the Allergy & Cold segment is further distinguished by Antihistamines and Decongestants, Pain Management by Analgesics and NSAIDs, and Vitamins & Nutritional Supplements by Multivitamins and Single Vitamins.

Integrating these segmentation lenses enables developers to prioritize technology investments and distribution strategies that align with the end-user needs and regulatory pathways for specific therapeutic targets, while also optimizing packaging and communication tactics to fit the chosen sales type and channel dynamics.

Regional strategic considerations and regulatory, manufacturing, and commercial adaptions required to successfully deploy oral disintegrating strips across global territories

Regional dynamics shape priorities for regulatory engagement, supply chain design, and commercial execution across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory frameworks and established pharmaceutical infrastructures favor streamlined clinical development and distribution partnerships, while patient-centric positioning and direct-to-consumer channels are increasingly influential. In Europe, Middle East & Africa, heterogeneous regulatory regimes and diverse reimbursement landscapes require nuanced go-to-market approaches and often necessitate localized stability and labeling strategies to meet varied national requirements.

In Asia-Pacific, rapid manufacturing scale-up, proximity to key raw material suppliers, and a large and diverse patient base create opportunities for both innovation and cost-competitive production models. Each region presents distinct considerations for intellectual property protection, regulatory dossier expectations, and post-market surveillance practices, which in turn affect timelines for product introduction and the selection of strategic partners. Cross-regional strategies that combine regional manufacturing hubs with local commercial partners can reduce logistical complexity and improve responsiveness to region-specific clinical needs.

A regional lens also influences decisions about clinical program design, comparator selection, and patient-reported outcome measures, all of which should be tailored to the regulatory expectations and healthcare utilization patterns of the target geography. Coordinated regional planning enhances the ability to scale manufacturing and distribution while maintaining compliance and maximizing adoption across diverse healthcare systems.

Key company-level differentiators in formulation platforms, manufacturing partnerships, quality systems, and intellectual property that shape competitive positioning in oral disintegrating strips

Competitive dynamics in the oral disintegrating strips space are shaped by companies that bring strength in formulation science, manufacturing capabilities, and route-to-market relationships. Leading developers differentiate through proprietary excipient systems, taste-masking technologies, or platform manufacturing know-how that enable higher drug loading, improved stability, and consistent dissolution performance. Contract development and manufacturing organizations play a pivotal role for clients seeking to outsource scale-up and production, offering technical transfer support and regulatory dossier preparation expertise.

Partnerships between innovator companies and specialist manufacturers are common, allowing brand owners to capitalize on third-party capabilities while preserving commercial focus. In addition, firms that invest in robust quality systems and humidity-controlled packaging solutions create competitive advantages by reducing product returns and ensuring longer shelf-life performance in diverse climates. Service providers that offer end-to-end support-from preformulation screening to commercial batch release-are particularly valuable for organizations that lack in-house film-formulation experience.

Intellectual property considerations and freedom-to-operate analyses are increasingly important as formulation platforms proliferate. Entities that protect core excipient combinations, manufacturing sequences, or coating techniques can create meaningful barriers to entry, particularly for higher-value therapeutic applications. For stakeholders evaluating partnerships or acquisitions, diligence should prioritize manufacturing reproducibility, regulatory track record, and the ability to adapt formulations for different distribution channels and end-user populations.

Actionable strategic recommendations for manufacturers and developers to ensure resilient supply chains, optimized formulations, regulatory alignment, and patient-centered commercialization

Industry leaders should adopt a pragmatic, patient-centered agenda that accelerates adoption while safeguarding quality and supply continuity. Begin by aligning formulation development with clearly defined end-user profiles and distribution routes so that taste-masking, strip sizing, and packaging are optimized for intended patients and channels. Simultaneously, invest in multiple validated suppliers for critical excipients and consider qualifying nearshore or regional partners to reduce exposure to tariff volatility and international logistics disruption.

Operationally, implement robust process controls and environmental monitoring for humidity-sensitive production steps, and prioritize packaging innovations that extend stability across diverse geographies. From a commercial perspective, build value propositions that emphasize adherence, ease of use, and clinical benefit, supported by real-world evidence or patient-reported outcomes where feasible. Engage early with regulatory authorities to clarify expectations for bioequivalence, dissolution parameters, and stability protocols to avoid downstream delays.

Finally, pursue targeted collaborations with contract manufacturers or clinical partners to accelerate time-to-market and de-risk scale-up. Use scenario planning to test the impact of input-cost variability, tariff shifts, and channel mix changes on pricing and profitability, and maintain a clear governance process for rapid decision-making when supply chain contingencies arise.

Rigorous research methodology combining primary stakeholder interviews, technical literature validation, supplier audits, and scenario analysis to underpin strategic insights

The research approach combines primary stakeholder engagement, technical literature synthesis, and qualitative validation to construct a robust view of the oral disintegrating strips landscape. Primary interviews were conducted with formulation scientists, regulatory affairs professionals, procurement leads, and commercial executives to capture cross-functional perspectives on development challenges, supply chain constraints, and adoption drivers. These conversations provided insight into technology trade-offs, manufacturing readiness, and the practical considerations that influence channel selection and labeling.

Technical literature and regulatory guidance documents were reviewed to validate dissolution targets, stability considerations, and bioavailability expectations for rapidly dissolving film formats. Supplier dialogues and manufacturing audits informed assessments of process capability, environmental control needs, and packaging requirements. Finally, scenario analysis and sensitivity testing were applied to evaluate the operational impact of input-cost changes, distribution shifts, and supplier disruptions, providing a practical foundation for the strategic recommendations offered.

This triangulated methodology ensures findings are grounded in both real-world operational experience and technical standards, offering decision-makers a balanced and actionable basis for R&D prioritization, supply chain design, and commercialization planning.

Concluding synthesis of technical progress, end-user drivers, and operational imperatives that determine successful commercialization of oral disintegrating strips

Oral disintegrating strips are at an inflection point where technical maturity, patient expectations, and commercial opportunity converge to create new pathways for product differentiation. Advances in formulation and manufacturing have addressed historical constraints, enabling broader applicability across therapeutic areas and patient populations. At the same time, evolving distribution models and demographic trends are increasing the value of patient-friendly, water-free administration formats that can improve adherence and patient satisfaction.

To capitalize on this momentum, stakeholders must integrate product design with pragmatic supply chain and regulatory strategies. Ensuring supplier diversity, investing in humidity-resilient packaging, and engaging regulators early are critical actions that reduce commercialization risk. Strategic collaborations and targeted investments in platform technologies can shorten development timelines and unlock higher-value therapeutic applications. Ultimately, success will favor organizations that combine technical excellence with operational resilience and clear, patient-centered commercial narratives.

By focusing on these coordinated priorities, developers and manufacturers can translate the promise of oral disintegrating strips into sustainable product portfolios that meet clinical needs and create durable competitive advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Disintegrating Strips Market, by Product Type

  • 8.1. Prescription
    • 8.1.1. Brand Name
    • 8.1.2. Generic
  • 8.2. Over-The-Counter
    • 8.2.1. Branded
    • 8.2.2. Private Label
  • 8.3. Nutraceutical
    • 8.3.1. Dietary Supplement
    • 8.3.2. Herbal Product

9. Oral Disintegrating Strips Market, by Technology

  • 9.1. Electrospinning
  • 9.2. Hot Melt Extrusion
  • 9.3. Solvent Casting

10. Oral Disintegrating Strips Market, by Therapeutic Area

  • 10.1. Allergy & Cold
    • 10.1.1. Antihistamines
    • 10.1.2. Decongestants
  • 10.2. Cardiovascular
  • 10.3. CNS Disorders
  • 10.4. Gastrointestinal
  • 10.5. Pain Management
    • 10.5.1. Analgesics
    • 10.5.2. NSAIDs
  • 10.6. Vitamins & Nutritional Supplements
    • 10.6.1. Multivitamins
    • 10.6.2. Single Vitamins

11. Oral Disintegrating Strips Market, by Distribution Channel

  • 11.1. Clinics & Others
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy

12. Oral Disintegrating Strips Market, by End User

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Oral Disintegrating Strips Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oral Disintegrating Strips Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Disintegrating Strips Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Oral Disintegrating Strips Market

17. China Oral Disintegrating Strips Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Aquestive Therapeutics, Inc.
  • 18.7. BioDelivery Sciences International, Inc.
  • 18.8. Corium International, Inc.
  • 18.9. CURE Pharmaceutical Holding Corp.
  • 18.10. GlaxoSmithKline plc
  • 18.11. Indivior PLC
  • 18.12. IntelGenx Technologies Corp.
  • 18.13. Johnson & Johnson
  • 18.14. LTS Lohmann Therapie-Systeme AG
  • 18.15. Medherant Limited
  • 18.16. Merck & Co., Inc.
  • 18.17. MonoSol Rx LLC
  • 18.18. NAL Pharma Co., Ltd.
  • 18.19. Novartis International AG

18.20. Other Noteworthy Players:

  • 18.21. Pfizer Inc.
  • 18.22. Sanofi S.A.
  • 18.23. Sumitomo Dainippon Pharma Co., Ltd.
  • 18.24. Sun Pharmaceutical Industries Ltd.
  • 18.25. Tesa Labtec GmbH
  • 18.26. Viatris Inc.
  • 18.27. ZIM Laboratories Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL DISINTEGRATING STRIPS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY BRAND NAME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY BRAND NAME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY BRAND NAME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRIVATE LABEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRIVATE LABEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRIVATE LABEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DIETARY SUPPLEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DIETARY SUPPLEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DIETARY SUPPLEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HERBAL PRODUCT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HERBAL PRODUCT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HERBAL PRODUCT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ELECTROSPINNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ELECTROSPINNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ELECTROSPINNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HOT MELT EXTRUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HOT MELT EXTRUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HOT MELT EXTRUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SOLVENT CASTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SOLVENT CASTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SOLVENT CASTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DECONGESTANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DECONGESTANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DECONGESTANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CNS DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CNS DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CNS DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY MULTIVITAMINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY MULTIVITAMINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY MULTIVITAMINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SINGLE VITAMINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SINGLE VITAMINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SINGLE VITAMINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CLINICS & OTHERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CLINICS & OTHERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY CLINICS & OTHERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 223. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 224. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 225. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 259. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 260. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 261. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 262. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. G7 ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL ORAL DISINTEGRATING STRIPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PRESCRIPTION, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY OVER-THE-COUNTER, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY NUTRACEUTICAL, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY ALLERGY & COLD, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY VITAMINS & NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA ORAL DISINTEGRATING STRIPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)